Baird lowered the firm’s price target on Insulet to $320 from $370 and keeps an Outperform rating on the shares. The firm updated its model followeng the filing of a patent infringement lawsuit against EOflow.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PODD:
- Insulet price target lowered to $273 from $319 at Citi
- Insulet price target lowered to $330 from $375 at Wells Fargo
- Insulet raises FY23 revenue growth view to 22%-25% from 18%-22%
- Insulet sees Q3 revenue up 18%-21% from last year
- Insulet reports Q2 EPS 38c, consensus 26c
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue